Analyse Protagonist Therapeutics, Inc. (PTGX) — Kairos Score 64/100

À propos de Protagonist Therapeutics, Inc.

Protagonist Therapeutics, Inc. operates as a discovery and development company in the United States. It develops Icotyde, a first-in-class investigational targeted oral peptide for the treatment of adults and pediatric patients 12 years of age and older with moderate-to-severe plaque psoriasis; and Rusfertide, a first-in-class investigational injectable mimetic of the natural hormone hepcidin in Phase 3 development for the treatment of the rare blood disorder polycythemia vera. The company is also developing PN-881, a potential best-in-class oral peptide IL-17 antagonist, for the treatment of immune-mediated skin diseases in Phase 1 clinical trials; PN-477 and PN-458, which are development candidates for the treatment of obesity; PN-8047, an orally administered hepcidin functional mimetic small molecule; L-4R alpha antagonist for the treatment of atopic dermatitis and moderate-to-severe asthma; and amylinR-based oral and subcutaneous mono- and poly-agonists for the treatment of obesity. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.

Informations clés

🕴️ Activité des initiés (90 jours)

11 transactions — 0 achats et 5 ventes déclarés par les dirigeants de Protagonist Therapeutics, Inc..

🏦 Hedge Funds

16 fonds institutionnels déclarent une position sur PTGX dans leur dernière déclaration trimestrielle SEC.

📰 Actualités récentes

15 articles récents sur PTGX.

• Protagonist Therapeutics Announces $300 Million Share Repurchase Program
• Protagonist (PTGX) Swings To A Profit As Two Drugs Near Blockbuster Status

🧠 Ce qui fait Kairos Insider

Au-dela des donnees brutes, nous agregeons et scoring tout le signal smart money pour vous donner une vue unique.